quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·78d
PRRelease
Entera Bio Ltd. logo
OPKO Health Inc. logo

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

ENTX· Entera Bio Ltd.OPK· OPKO Health Inc.
Health Care
Original source

Companies

  • ENTX
    Entera Bio Ltd.
    Health Care
  • OPK
    OPKO Health Inc.
    Health Care

Recent analyst ratings

  • Nov 20OPKUpdateAnalyst-
  • Oct 31OPKUpdateJefferies$1.60
  • Apr 25OPKUpdateAnalyst-
  • Jun 29OPKUpdateBarrington Research$2.00
  • Dec 15OPKUpdateH.C. Wainwright$3.00
  • Jan 24OPKUpdateBarrington Research-

Related

  • PR1d
    OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
  • PR2d
    OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
  • PR3d
    BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
  • PR9d
    Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
  • PR15d
    OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
  • PR17d
    Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
  • SEC20d
    Entera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
  • PR21d
    Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022